HRT Financial’s Ocular Therapeutix OCUL Stock Holding History

HRT Financial’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6M	Buy	1,077,090 +367,872	+52%	+$3.33M	0.02%	756
2026 Q1	$6.01M	Buy	709,218 +306,255	+76%	+$2.92M	0.02%	893
2025 Q4	$4.89M	Buy	402,963 +80,049	+25%	+$972K	0.02%	797
2025 Q3	$3.77M	Buy	+322,914	New	+$3.86M	0.01%	810
2023 Q3	–	Sell	-54,360	Closed	-$280K	–	2888
2023 Q2	$280K	Buy	+54,360	New	+$323K	﹤0.01%	1666
2022 Q4	–	Sell	-10,868	Closed	-$45K	–	2938
2022 Q3	$45K	Buy	+10,868	New	+$54.7K	﹤0.01%	2451
2022 Q2	–	Sell	-10,370	Closed	-$51K	–	3485
2022 Q1	$51K	Buy	+10,370	New	+$57.5K	﹤0.01%	2744
2021 Q4	–	Sell	-71,736	Closed	-$717K	–	3806
2021 Q3	$717K	Buy	71,736 +31,331	+78%	+$352K	﹤0.01%	1696
2021 Q2	$572K	Buy	+40,405	New	+$614K	0.01%	1636
2020 Q4	–	Sell	-11,165	Closed	-$84K	–	2279
2020 Q3	$84K	Buy	+11,165	New	+$92.7K	﹤0.01%	1573
2020 Q1	–	Sell	-19,800	Closed	-$78K	–	1184
2019 Q4	$78K	Buy	+19,800	New	+$68.8K	﹤0.01%	1045

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial's OCUL Position: Q2 2026 in Review

HRT Financial increased its Ocular Therapeutix (OCUL) stake by 52% in Q2 2026, buying an estimated $3.33M and bringing the position to 1,077,090 shares worth $10.6M. The position accounts for 0.02% of the portfolio, ranked #756.

HRT Financial first reported a position in OCUL in Q4 2019 and has held it in 11 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

HRT Financial held 1,077,090 shares of Ocular Therapeutix worth $10.6M as of Q2 2026.
HRT Financial bought 367,872 Ocular Therapeutix shares in Q2 2026, an estimated $3.33M.
Ocular Therapeutix made up 0.02% of HRT Financial's portfolio in Q2 2026, its #756 holding.
HRT Financial first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 11 quarters since.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.